Skip to main content

Table 1 Baseline demographic and clinical characteristics of patients with AS: comparison of patients entering double-blind and open-label extension study periods

From: Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis

  Week 24 of ATLAS (n = 315) Open-label extension (n = 288) P value a
Age, years 42.2 ± 11.57 42.4 ± 11.65 0.848
Male, n (%) 236 (74.9) 219 (76.0) 0.777
White, n (%) 301 (95.6) 276 (95.8) 1.000
Disease duration, years 10.9 ± 9.47 10.9 ± 9.43 0.953
BASDAI score, 0–10 cm 6.3 ± 1.69 6.3 ± 1.70 0.997
BASFI score, 0–10 cm 5.4 ± 2.21 5.4 ± 2.19 0.900
SF-36 PCS, 0–50 32.5 ± 7.98 32.4 ± 8.00 0.846
SF-36 MCS, 0–50 43.7 ± 11.57 44.0 ± 11.48 0.804
SF-36 domain scales
   Physical Function 47.1 ± 22.08 46.8 ± 22.49 0.893
   Role–Physical 20.3 ± 30.02 20.9 ± 30.25 0.808
   Bodily Pain 55.9 ± 25.06 55.9 ± 25.08 0.979
   General Health 42.6 ± 19.82 42.6 ± 20.06 0.997
   Vitality 31.1 ± 16.12 30.9 ± 16.12 0.875
   Social Function 33.1 ± 17.49 32.9 ± 17.30 0.895
   Role–Emotional 54.4 ± 42.98 56.1 ± 42.90 0.641
   Mental Health 61.7 ± 19.19 61.8 ± 19.17 0.952
ASQOL, 0–18 10.3 ± 4.29 10.3 ± 4.29 0.945
  1. Data are mean ± standard deviation unless otherwise noted.
  2. aP-values for comparing means based on two-sample paired Student t-tests; P-values for comparing percentages based on Fisher's exact tests.
  3. AS = ankylosing spondylitis; ASQOL = AS Quality of Life Questionnaire; ATLAS = Adalimumab Trial Evaluating Long-Term Efficacy and Safety in AS; BASDAI = Bath AS Disease Activity Index; BASFI = Bath AS Functional Index; HRQOL = health-related quality-of-life; MCS = Mental Component Summary; PCS = Physical Component Summary; SF-36 = Short Form-36 Health Survey.